Success Story: 14-Day EB1A Approval! Instructor Reaches Milestone with Our Expert Support

Client’s Testimonial:

“I am truly grateful to the NAILG team for their outstanding professionalism, responsiveness, and deep understanding of the EB-1A process. Their strategic guidance helped me present my work in the most compelling way, and I was thrilled to receive approval without an RFE. Thanks to their support, I can now continue my research and contribute to the field of cardiovascular medicine here in the United States.”

On June 27^th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for an Instructor in the Field of Cardiovascular Medicine (Approval Notice).

General Field: Cardiovascular Medicine

Position at the Time of Case Filing: Instructor

Country of Origin: Belgium

State of Residence at the Time of Filing: California

Approval Notice Date: June 27^th, 2025

Processing Time: 14 days (Premium Processing Requested)

Case Summary:

We are pleased to share the success story of an EB1A (Alien of Extraordinary Ability) approval granted to a cardiovascular medicine researcher from Japan whose work is helping advance therapeutic strategies for heart failure and myocardial infarction. At the time of filing, the client was employed as a researcher developing extracellular vesicle-based therapies for cardiac dysfunction and had already made groundbreaking contributions to stem cell technology and mitochondrial biology. The petition was filed under premium processing and approved in just 14 days.

Well-Positioned to Advance the Proposed Endeavor:

When this client approached NAILG, we immediately recognized his strong candidacy due to his distinctive specialization in cardiovascular drug development through stem cell cardiomyocyte-derived mitochondrial-rich extracellular vesicles (M-EVs). His work has focused on restoring cardiac performance in myocardial infarctions by harnessing innovative cellular therapy approaches. After reviewing his extensive research background and impact on the field, we successfully demonstrated his extraordinary ability to USCIS.

Research with Substantial Merit and National Importance:

The client’s research targets a critical need in regenerative cardiovascular medicine, improving mitochondrial function in damaged cardiac tissue through stem-cell-derived vesicles. His scholarly output includes 15 peer-reviewed journal articles, 13 first-authored abstracts, 2 preprints, and 1 book chapter. His work has been cited 1,274 times, and he has completed at least 29 peer reviews for prestigious journals. The petition outlined how his original discoveries in cardiac repair have enabled further scientific progress in areas like ischemic stroke, myocardial repair, and chronic wound treatment.

Supportive Expert Testimonials:

The petition was further strengthened with 4 letters of recommendation from distinguished researchers in the field, including three independent advisory opinions. These experts confirmed the impact, originality, and global relevance of the client’s work.

“It is crucial to support the continuation of [Client’s] work for the advancement of cardiovascular medicine research and for the benefit of the nation.”

Final Result:

With strong documentation of his original scientific contributions, high-impact authorship, and global influence in cardiovascular medicine, the EB1A petition was approved within just two weeks of filing. We are proud to have helped another extraordinary researcher continue his innovative work in the United States through our professional guidance at NAILG.

North America Immigration Law Group (Chen Immigration Law Associates) is a U.S. immigration law firm dedicated to representing corporations, research institutions, and individuals from all 50 U.S. states regarding I-140 immigration petitions. We specialize in employment-based immigration petition and have a proven record of high success rate for the categories of: EB2-NIW (National Interest Waiver), EB1-A (Alien of Extraordinary Ability), EB1-B (Outstanding Researcher/Professor) and O-1 (Alien of Extraordinary Ability).

Our Ten Thousand I-140 Approvals Provide Unprecedented Insight into the USCIS Adjudication Trend

With more than 58,000 EB-1A, EB-1B, EB-2 NIW and O-1 cases approved, we have first hand information on the manner in which the USCIS adjudicate I-140 cases. As the USCIS has constantly changed its adjudication standards for the EB-1A, EB-1B and EB-2 NIW categories, our firm's huge database of successful cases gives you unprecedented insight to USCIS adjudication trends. We carefully analyze the data for all of our cases and apply the results of our analyses toward giving our clients up-to-date advice and adapting our strategies such that we remain on par with the ever-shifting landscape of immigration law in the U.S. With us, you will always have access to important updates, strategies, and information so that you can make the most informed decisions about your case.

We Have Helped Hundreds and Thousands of Clients with Credentials and Backgrounds Similar to Yours

With our exceedingly large number of successful petitions, no matter what credentials you have, no matter your background and field of expertise, no matter your visa status or nationality, chances are we have helped hundreds or even thousands of clients just like you. Our clients are usually impressed with how well we understand their research and work. Our insight and understanding stems from the fact that we have handled many cases with elements similar to yours already, and this helps us devise the best strategies for each individual petition.

Vast Majority of Clients Came to Us Because of Referrals

For years, our firm has attracted new clients based solely on word of mouth, recommendations, and the positive collaboration experiences shared with them by their friends and family. We take pride in our reputation and work hard to ensure that we provide a green card application experience that our clients are happy to share with their friends and colleagues. That is how our cumulative total of approved cases grew from 600 in 2013 to over 58,000 in 2025.